{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:35:29Z","timestamp":1787585729297,"version":"build-2736575974"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.msard.2020.102058","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T11:40:21Z","timestamp":1584186021000},"page":"102058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6695-5684","authenticated-orcid":false,"given":"Marjo","family":"Nylund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tytti","family":"Vuorinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5881","authenticated-orcid":false,"given":"Laura","family":"Airas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102058_bib0001","unstructured":"European Medicines Agency (2018) - European public assessment report (EPAR) - Ocrevus. Ema."},{"issue":"2","key":"10.1016\/j.msard.2020.102058_bib0002","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12016-015-8491-x","article-title":"Eosinophilic drug allergy","volume":"50","author":"Kuruvilla","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.msard.2020.102058_bib0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdcr.2018.11.017","article-title":"Nivolumab-associated DRESS syndrome: a case report","volume":"5","author":"Lu","year":"2019","journal-title":"JAAD Case Rep."},{"issue":"4","key":"10.1016\/j.msard.2020.102058_bib0004","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1212\/WNL.0000000000005854","article-title":"Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy","volume":"91","author":"Rauer","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2020.102058_bib0005","first-page":"50","article-title":"DRESS syndrome caused by efalizumab","volume":"33","author":"White","year":"2008","journal-title":"Clin. Exp. Dermatol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:48:22Z","timestamp":1761900502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820301346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":5,"alternative-id":["S2211034820301346"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102058","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102058"}}